Swarup Kumar, MD

Swarup Kumar, MD, also details treating incarcerated patients with bispecifics and pursuing cure-focused therapy sequencing in myeloma.

Swarup Kumar, MD, discusses how myeloma programs can bridge gaps between academic innovation and community access for bispecific antibody therapy.

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.